U.S. markets open in 4 hours 12 minutes
  • S&P Futures

    +25.25 (+0.65%)
  • Dow Futures

    +236.00 (+0.75%)
  • Nasdaq Futures

    +92.50 (+0.71%)
  • Russell 2000 Futures

    +29.00 (+1.30%)
  • Crude Oil

    +0.91 (+1.52%)
  • Gold

    -9.10 (-0.52%)
  • Silver

    -0.16 (-0.59%)

    +0.0012 (+0.10%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.54 (-2.31%)

    +0.0024 (+0.17%)

    +0.1830 (+0.17%)

    +2,596.37 (+5.30%)
  • CMC Crypto 200

    +43.44 (+4.40%)
  • FTSE 100

    +75.20 (+1.14%)
  • Nikkei 225

    +150.93 (+0.51%)

Did You Manage To Avoid ProPhase Labs's (NASDAQ:PRPH) 41% Share Price Drop?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
  • Oops!
    Something went wrong.
    Please try again later.

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Investors in ProPhase Labs, Inc. (NASDAQ:PRPH) have tasted that bitter downside in the last year, as the share price dropped 41%. That's disappointing when you consider the market returned 16%. However, the longer term returns haven't been so bad, with the stock down 11% in the last three years. The falls have accelerated recently, with the share price down 14% in the last three months.

See our latest analysis for ProPhase Labs

ProPhase Labs isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

ProPhase Labs's revenue didn't grow at all in the last year. In fact, it fell 24%. That's not what investors generally want to see. The stock price has languished lately, falling 41% in a year. That seems pretty reasonable given the lack of both profits and revenue growth. It's hard to escape the conclusion that buyers must envision either growth down the track, cost cutting, or both.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

NasdaqCM:PRPH Income Statement, October 29th 2019
NasdaqCM:PRPH Income Statement, October 29th 2019

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

What about the Total Shareholder Return (TSR)?

Investors should note that there's a difference between ProPhase Labs's total shareholder return (TSR) and its share price change, which we've covered above. Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. ProPhase Labs hasn't been paying dividends, but its TSR of -37% exceeds its share price return of -41%, implying it has either spun-off a business, or raised capital at a discount; thereby providing additional value to shareholders.

A Different Perspective

While the broader market gained around 16% in the last year, ProPhase Labs shareholders lost 37%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 14%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. If you would like to research ProPhase Labs in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.